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Abstract
This study presents a dose-response-time (DRT) analysis based on a large pre-
clinical biomarker dataset on the interaction between nicotinic acid (NiAc) and
free fatty acids (FFA). Data were collected from studies that examined diﬀerent
rates, routes, and modes of NiAc provocations on the FFA time course. All in-
formation regarding the exposure to NiAc was excluded in order to demonstrate
the utility of a DRT model. Special emphasis was placed on the selection pro-
cess of the biophase model. An inhibitory Imax-model, driven by the biophase
amount, acted on the turnover rate of FFA. A second generation NiAc/FFA
model, which encompasses integral (slow buildup of tolerance - an extension
of the previously used NiAc/FFA turnover models) and moderator (rapid and
oscillatory) feedback control, was simultaneously ﬁtted to all time courses in
normal rats. The integral feedback control managed to capture an observed
90% adaptation (i.e., almost a full return to baseline) when 10 days constant-
rate infusion protocols of NiAc were used. The half-life of the adaptation process
had a 90% prediction interval between 3.5-12 h in the present population. The
pharmacodynamic parameter estimates were highly consistent when compared
to an exposure-driven analysis, partly validating the DRT modelling approach
and suggesting the potential of DRT analysis in areas where exposure data are
not attainable. Finally, new numerical algorithms, which rely on sensitivity
equations to robustly and eﬃciently compute the gradients in the parameter
optimization, were successfully used for the mixed-eﬀects approach in the pa-
rameter estimation.
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1. Introduction
The traditional pharmacokinetic-pharmacodynamic (PK-PD) modelling ap-
proach is generally based on known plasma kinetics when the PD properties are
assessed. Dose-response-time (DRT) data analysis is an alternative to exposure-
driven kinetic - dynamic modelling when exposure data are sparse or lacking.5
This involves studies where the pharmacological response precedes the systemic
exposure (e.g. pulmonary drug administration) or when the drug is locally ad-
ministered (e.g. in ophthalmics). In DRT analyses the pharmacological eﬀect
is assumed to contain some kinetic properties whereby a biophase function can
be developed and in turn acts as a `driving' function of the pharmacological ef-10
fect. The biophase function is assessed using various structures from a biophase
model library when the DRT model is ﬁtted to data. This biophase library
consists of feasible models derived from the kinetic information in the response-
time course in combination with knowledge of the physiology.
DRT data analysis dates back to the 1960's and 1970's when Smolen [53,15
54, 55] and Levy [39] introduced the concept. Smolen used response data to
quantify the bioavailability and biokinetic behaviour of a mydriatic drug after
oral and ophthalmic administration whilst Levy derived a relation between the
pharmacological eﬀect and elimination rate of a mydriatic drug. Since the work
of Smolen, DRT data analysis has been proven to be applicable to novel sys-20
tems where the kinetics and/or dynamics behave non-linearly, when there are
time-delays in the response data, and when the system contains feedback mech-
anisms [24]. The technique has successfully been applied in models of the muscle
relaxant drug vecuronium [14, 22, 21, 64], antinociceptive drugs [1, 26, 24], oph-
thalmic drugs [24, 41], antidepressants [28], psycho-motor stimulants [26], drugs25
to treat chronic obstructive pulmonary disease (COPD) [65], and osteoporosis
[46]. For a review and theoretical guide to DRT analysis see Gabrielsson et
al. [24, 26]. DRT models go under the name of K-PD (K for kinetic) models
in some analyses [28, 29, 35, 46, 65]. However, in the latter case the biophase
turnover rate, rather than the biophase amount, is driving the response.30
NiAc has long been used as a therapeutic agent to treat dyslipidemia. The
drug eﬀectively suppresses the level of triglycerides and low-density lipopro-
tein cholesterols in plasma whilst elevating the level of high-density lipoprotein
cholesterol [16]. NiAc inhibits hydrolysis in adipose tissue by activating the G-
coupled receptor GPR109A, which in turn inhibits the adenylyl cyclase, leading35
to reduced levels of cyclic adenosine monophosphate (cAMP). The cAMP ac-
tivates the enzyme protein kinase A which phosphorylates hormone-sensitive
lipase that in turn hydrolyses triglycerides into FFA (Fig. 1) [44].
We sought to further demonstrate the utility of DRT data analysis. To do
so, we analysed a rich preclinical data set containing several individuals (a total40
of 95 rats and response-time courses) and provocations (constant rate infusions
at three dosage levels, step-wise increasing infusion at two dosage levels, and
oral administration at three dosage levels) of the NiAc - FFA interaction. Avail-
able exposure data for NiAc were intentionally excluded in order to use a DRT
approach. The developed DRT model was compared and validated by means of45
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Figure 1: Mechanism of NiAc-induced inhibition of lipolysis. NiAc activates the G-coupled
receptor GPR109A, which in turn inhibits the adenylyl cyclase, reducing the production of
cyclic adenosine monophosphate (cAMP) from adenosine triphosphate. cAMP activates pro-
tein kinase A, which phosphorylates hormone-sensitive lipase, thereby regulating the hydroly-
sis of triglycerides into FFA. Thus, NiAc binding will inhibit lipolysis leading to reduced levels
of FFA. Adapted from Oﬀermanns 2006 [44].
exposure-driven kinetic/dynamic results, where the pharmacokinetic properties
of NiAc had been thoroughly characterized [3].
The applied pharmacodynamic model is an extended and signiﬁcantly im-
proved version of a previously utilised feedback model [2, 4, 6, 25, 59]. This
second-generation feedback model uses an integral feedback control mechanism50
to capture the slowly developing tolerance. This model is aﬀected by a biophase
model that drives the inhibitory drug-mechanism function. The biophase model
was selected using an iterative modelling approach where the biophase model
was systemically reﬁned in order to better capture the dynamic behaviour seen
in the data. This study presents an approach to the development of the bio-55
phase model structure simultaneously with the pharmacodynamic model. In
light of the aforementioned, DRT analyses do not fully replace exposure-driven
analyses, particularly in safety assessment.
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2. Materials and methods
2.1. Background and data sources60
The pre-clinical data set consisted of FFA response-time series of 95 male
Sprague-Dawley rats under NiAc provocation. These data have previously been
described by Ahlström et al. [3, 5, 7, 4, 6, 33] and Tapani et al. [59]. A thor-
ough description of the animals and surgical procedure, experimental design,
and analytical assay can be found in Ahlström et al. [4].65
All experiments were designed and conducted at AstraZeneca, Mölndal Swe-
den, and approved by the Ethics Committee for Animal Experiments, Gothen-
burg, Sweden (EA 100868).
2.2. Selection process of biophase models
The DRT data analysis is based on the assumption that the pharmacological70
response contains some kind of kinetic information and is driven by NiAc in a
hypothetical biophase compartment. The ﬁt of the pharmacodynamic model
(given in Sec. 2.4) to the data informs about the soundness of choice of the
driving biophase function. Depending on the route of administration, the input
is either approximated to be directly into the biophase (intravenous dosing)75
or absorbed into the biophase (oral dosing). The biophase model structures
were modiﬁed through a series of steps where data from diﬀerent routes and
rates of administration were sequentially assessed (see Table 1). In a pair-
wise accept-reject procedure, two models were qualitatively and quantitatively
compared and the one considered to be the better model, in terms of goodness-80
of-ﬁt, was selected and further challenged by more complex data (see Table 1).
The goodness-of-ﬁt was based on the likelihood function value and by graphical
inspection of the function plots.
Step I. The ﬁrst biophase model that was evaluated consisted of a zero-order
input into and ﬁrst-order elimination from the biophase (Fig. 2b). To capture85
the disposition characteristics, the model was evaluated using response-time
data derived from diﬀerent constant-rate intravenous infusion experiments.
Step II. The next biophase model to be evaluated consisted of zero-order input
and Michaelis-Menten elimination from the biophase (Fig 2c). This model was
evaluated using the same data as in step I.90
The model that best described (in terms of goodness-of-ﬁt) the dynamics,
using the response-time data derived from diﬀerent constant-rate intravenous
infusion experiments, was kept for the later stages of the biophase evolution. In
this case, the models used in step I and II had close to similar objective func-
tion values and were indistinguishable by graphical inspection of the function95
ﬁts. However, in accordance with the principle of Occam's razor, and by apply-
ing the Akaike Information Criterion [8], the zero-order input and ﬁrst-order
elimination model was chosen.
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Step III. When a model for the biophase elimination model was set, response-
time data derived from experiments for diﬀerent oral dosages were included100
in order to address the biophase absorption. The ﬁrst biophase absorption
model that was evaluated consisted of ﬁrst-order input and elimination from
the biophase (Fig. 2d).
Step IV. The ﬁnal absorption model that was evaluated consisted of Michaelis-
Menten input and ﬁrst-order elimination (Fig 2e). This model was evaluated105
using the same data as in step III.
The model in step IV had a higher likelihood function value and a substan-
tially better ﬁt when inspecting the function plots than the model in step III,
and was therefore selected.
2.3. The ﬁnal biophase model110
The biophase was modelled as
dAb
dt
= Inf− k ·Ab, (1)
for intravenous administration of NiAc, with initial condition
Ab(0) = 0 (2)
where Ab denotes the biophase drug amount, k the biophase elimination rate
constant, and Inf the infusion rate to the biophase. The infusion rate was mod-
elled as a step function with either constant rate during the infusion period, or115
stepwise decreasing infusion rates, to mimic the infusion regimens used in the
experiments.
Orally administered NiAc was assumed to be eliminated from the gut ac-
cording to a Michaelis-Menten type of saturable process
dAg
dt
= −Vmax,g ·Ag
Km,g +Ag
(3)
with initial condition120
Ag(0) = D (4)
where Ag denotes the amount of drug in the gut, Vmax,g the maximal elimination
rate from the gut,Km,g the Michaelis-Menten constant (representing the amount
in the gut at half maximal rate), and D the oral drug dose. The drug amount
that is eliminated from the gastro-intestinal tract is absorbed into the biophase,
giving the biophase equation125
dAb
dt
=
Vmax,g ·Ag
Km,g +Ag
− k ·Ab (5)
with initial condition
Ab(0) = 0 (6)
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where Ab denotes the biohase drug amount and k the biophase elimination rate
constant.
2.4. Structure of the FFA feedback model
The fundamental dynamics of FFA are described in terms of a turnover130
equation
dR
dt
= k˜in − k˜out ·R (7)
where R denotes the FFA level, and k˜in and k˜out are functions describing the
lumped eﬀects of NiAc, and insulin and other hormones, on the turnover and
fractional turnover of FFA, respectively. The NiAc-induced action on FFA is
described by means of an inhibitory drug mechanism function given by135
I(Ab) = 1− Imax ·A
γ
b
IDγ50 +A
γ
b
(8)
where Ab denotes the biophase drug amount, Imax the eﬃcacy, ID50 the po-
tency, and γ the Hill exponent.
The FFA level in the model is aﬀected by a chain of moderator compart-
ments M1, . . . ,M8. These moderator compartments represent a conglomerate
of insulin, and other hormonal, regulators of the FFA disposition. Insulin, for140
example, acts as a dual regulator on the FFA level via rapid inhibition of the
lipolysis and slow re-esteriﬁcation of FFA to triglycerides [23, 50, 58]. This
is captured by the dynamics of the ﬁrst M1 and the last M8 moderator com-
partment, respectively. The moderators are described by the following set of
equations145
dM1
dt
= ktol · (R−M1)
dM2
dt
= ktol · (M1 −M2) (9)
...
dM8
dt
= ktol · (M7 −M8)
where R denotes the FFA level and ktol the fractional turnover rate of the
moderators. Consequently, all moderator compartments have the same transit
time of 1/ktol. The moderators are initially assumed to be in equilibrium with
the response, thus
M1(0) = . . . =M8(0) = R0 (10)
where R0 is the FFA baseline level. The number of moderator compartments150
selected was previously discussed by Ahlström et al. [7].
Long-term exposure to NiAc has proven to induce insulin resistance in adipocytes
[20, 47]. This is believed to be a consequence of down-regulated gene expressions
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of the insulin and β-adrenergic pathways in adipose tissue [32]. Insulin resis-
tance ultimately leads to full systemic adaptation with a FFA level that returns155
to its baseline within a few days [37, 45]. This slow and complete adaptation is
captured by an integral feedback controller, with output u(t), that slowly forces
deviating FFA levels back towards their baseline R0 despite persistent pertur-
bations such as constant rate infusion of NiAc. The integral controller is given
by160
u(t) = Ki
t∫
0
(
1− R(τ)
R0
)
dτ (11)
whereKi denotes the integral gain parameter (here-after referred to as the adap-
tation rate). The integral controller may also be expressed as a rate equation
du
dt
= Ki ·
(
1− R(t)
R0
)
(12)
with initial condition
u(0) = 0. (13)
The expanded turnover equation of FFA under NiAc provocation is given by165
dR
dt
= kin · (1 + u(t)) · 1(
M1
R0
)p · I(Ab)
− kout ·
(
M8
R0
)
·R (14)
with initial condition
R(0) = R0 (15)
where R denotes the FFA level, kin the basal turnover rate, kout the basal frac-
tional turnover rate, R0 the baseline of response, u(t) the integral controller,
p the ampliﬁcation factor, and M1 and M8 the ﬁrst and last moderator, re-
spectively. The moderators are normalized in the turnover Eq. 14 with the170
baseline FFA value R0. The levels of the moderators follow the level of the
FFA according to Eq. 9. In turn, the ﬁrst moderator M1 modiﬁes the turnover
rate kin, ampliﬁed with the exponent p, whilst the last moderator M8 modiﬁes
the fractional turnover rate kout. These feedback mechanisms represent the fast
inhibition of lipolysis and the slower re-esteriﬁcation of FFA to triglycerides,175
triggered by insulin and other hormones, that strive to dampen ﬂuctuations
in the FFA level. Furthermore, when the FFA level drops below the baseline
level, the integral controller, given by Eq. 11, will accumulate and provide a
positive contribution to the turnover rate kin of FFA. Similarly, when the FFA
level increases and rises above the baseline level, the integral controller will ac-180
cumulate and provide a negative contribution to the turnover rate. The full
pharmacodynamic model structure is depicted in Fig 3.
7
2.5. Initial parameter estimates
At time zero, before administration of NiAc, the system is in steady-state,
with the moderators set at R0. Consequently, the turnover equation (Eq. 14)185
pre-NiAc administration is given by
dR
dt
= kin − kout ·R0 = 0. (16)
A simple rearrangement gives the relation
R0 =
kin
kout
(17)
and hence the system may be simpliﬁed with one of the parameters R0, kin, or
kout removed in the parameter estimation. In this study, kin was estimated as a
secondary parameter from the product of R0 and kout. The initial estimate of190
the FFA baseline level R0 was taken as the mean response at time zero.
Since the minimum FFA level is close to zero, initially for high NiAc dosages,
we conclude that NiAc has a high eﬃcacy and that Imax is close to 1. Further-
more, for high NiAc infusion rates, the inhibitory drug-mechanism function
becomes saturated whilst the moderators are initially in steady-state with the195
response. Using this, and the initiate estimate of Imax Eq. 14 can be approxi-
mated as
dR
dt
≈ −kout ·R (18)
or
R(t) ∼= R0e−koutt. (19)
By means of this relation, kout can be estimated from the initial down-swing of
the response on a semi-logarithmic scale.200
The Hill exponent γ and the ampliﬁcation factor p were initially set to 1
since little was known about the respective parameter values. The remaining
parameters were estimated from simulations of the system.
2.6. Modelling random eﬀects and residual variability
The extent of the data set allowed for mixed-eﬀects to be included in the205
model, i.e., speciﬁc parameter values were allowed to vary within the population.
To identify which parameters had a signiﬁcant spread in the population, individ-
ual parameter ﬁtting was applied. The ﬁve parameters with highest variability,
in terms of coeﬃcient of variation, were then selected as individual parameters;
the rest were considered as population parameters. The parameters chosen to210
vary in the population were k, Ki, R0, kout, and ktol. These parameters were as-
sumed to be uncorrelated (to simplify the model) and log-normally distributed
(to keep the parameters positive).
The individual parameter estimates are referred to as Empirical Bayes Estimates
(EBE's) and their individual ﬁts and the model assumptions were quantiﬁed by215
their corresponding η-shrinkage [51, 13].
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2.7. Parameter estimation
The parameter estimation of the DRT model in this study was performed
using a mixed-eﬀects modelling framework implemented in Mathematica, devel-
oped at the Fraunhofer-Chalmers Research Centre for Industrial Mathematics220
(Gothenburg, Sweden) [9]. This framework is designed to estimate parameters
in non-linear mixed eﬀects models where the underlying dynamical system is
either described by a set of ordinary or stochastic diﬀerential equations. The
framework relies on the ﬁrst-order conditional estimation (FOCE) [38], with or
without interactions, to estimate the individual likelihoods of the population225
likelihood function. The argument that maximises the population likelihood
function is found using the BroydenFletcherGoldfarbShanno algorithm [43]
where the gradient of the objective function is calculated using the so-called
sensitivity equations.
3. Results230
Observed response-time series with corresponding population model ﬁts and
90% Monte Carlo prediction intervals [49] are illustrated in Fig. 4. The FFA
concentrations were suppressed in all animals receiving NiAc. A clear adapta-
tion towards the FFA baseline was only seen for the individuals that received a
300min constant rate infusion of NiAc (Fig. 4d-4f). This functional adaptation235
was more pronounced the higher the infusion rate. All infusion regimens gave
rise to a rebound eﬀect, i.e., the FFA level overshoots the initial baseline, after
the infusions were stopped. The rebound eﬀect was more pronounced the higher
the infusion rate. This eﬀect was followed by apparent oscillations in the FFA
level around the baseline, which were more pronounced with the extended NiAc240
infusion regimens (longer duration of the infusions and higher NiAc doses). The
rats that received an oral dose of NiAc experienced an FFA drop followed by an
approximately constant FFA level (Fig. 4i-4k). The higher the dose, the longer
the rats stayed at a suppressed and approximately constant FFA level. This was
followed by rebound and oscillations. The suppression of FFA, the occurrence245
of rebound, and the extent of the oscillations were more pronounced the higher
the oral dose.
The estimated population biophase amount-time courses are illustrated in
Fig. 5. For the constant rate NiAc infusions, the biophase amount quickly
reached steady-state (Fig. 5a-5f). The wash-out kinetics were rapid with a half-250
life of around 2min. For the highest oral doses, the biophase amount declined
in a non-linear fashion post-peak due to absorption-rate limited elimination of
NiAc (Fig. 5k).
Observed individual FFA response-time series with individually ﬁtted FFA
response levels are illustrated in Fig. 6 for one individual per administration255
route and rate. The model captured the individual behaviour for all individu-
als. Speciﬁcally, the slow adaptation, in the individuals that received a 300-min
infusion of NiAc, was captured by the integral feedback control present in the
pharmacodynamic model (Fig. 6d-6f).
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The ﬁtted population parameters and inter-individual variations with cor-260
responding relative standard errors for the full system are illustrated in Table
2. The biophase elimination rate constant k and the fractional turnover rate of
FFA kout are of the same order of magnitude, indicating little to no time-delay
between biophase kinetics and FFA dynamics. Since the absorption into the
biophase is non-linear, we observed typical absorption-rate limited elimination265
at higher oral doses of NiAc. The estimated Km,g of about 40 µmol kg
−1 implies
that the two higher oral doses (81.2 and 812 µmol kg−1) approach and exceed
saturation.
The eﬃcacy parameter Imax was estimated as 0.893 < 1; therefore, NiAc
cannot completely suppress FFA levels. The estimated biophase potency ID50270
shows that the drug-mechanism function (Eq. 8) will be saturated at the highest
infusions and for all the oral doses (Fig. 5). The estimated Hill exponent γ indi-
cates a steep NiAc biophase amount - FFA response relationship at equilibrium.
The rate constants kout, ktol, and Ki all have diﬀerent orders of magnitude, and
thus act over diﬀerent time-scales. Half-lives for the three rate constants with275
90% non-parametric bootstrap prediction intervals [18] are given in Table 3.
The pivotal systems (kout, ktol, Ki, p) and drug parameters (Imax, γ) were
compared to estimates from an exposure-driven analysis, using the same dy-
namic model. The estimates are given in Table 4.
3.1. Model predictions280
By using the predicted population parameters, we explored the long-term ef-
fects of NiAc provocation on FFA level for the infusion rate of 0.17 µmol kg−1min−1
(Fig. 7), aiming at a therapeutic plasma concentration of NiAc of 1µmol [4].
The model predicted 90% adaptation within approximately 10 days of constant
NiAc exposure. The eﬀect of the fast moderator (M1) feedback can be seen im-285
mediately after the initial drop, where the system rapidly returns towards the
baseline. The eﬀect of the slower moderator feedback (M8) is seen as a slower
terminal return with oscillations in the FFA level. The eﬀect of the integral
feedback controller is seen as the slow return to baseline over time.
3.2. Structural identiﬁability290
The model structure was proven to be structurally locally identiﬁable. Iden-
tiﬁability was tested using the Exact Arithmetic Rank (EAR) approach [11,
36, 48]. This approach requires that the functions in the system of diﬀerential
equations are rational polynomial expressions in the variables and parameters.
In this study, the inhibitory drug-mechanism function and the feedback func-295
tion of the ﬁrst moderator compartment did not fulﬁl this requirement since
the state variables were raised to the powers of γ and p, respectively (which
are real-valued). However, this problem is solved by re-writing the system in
rational form by the introduction of auxiliary variables [40]. For example, let
B(t) = Aγb(t) (20)
B(0) = B0 (= A
γ
b(0)). (21)
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Then we have that300
dB
dt
= γ
B(t)
Ab(t)
· dAb
dt
, (22)
and by introducing the parameter I˜D50(=ID
γ
50) the non-rational functions in
the inhibitory drug-mechanism function can be written as
1− Imax ·B(t)
I˜D50 +B(t)
(23)
which is a rational expression of the parameters and the variables.
3.3. Shrinkage analysis
Shrinkage analysis was used in order to quantify the individual parameter305
assumptions (log-normality) and to quantify the model ﬁts [51]. The η-shrinkage
of the EBE's are given in Table 2. The standard deviation of the residual
additive error and the ε-shrinkage for the infusion and oral data are given in
Table 5.
4. Discussion310
DRT data analysis has previously proved to be an alternative approach to
exposure-driven modelling when exposure data are sparse or absent [14, 22, 21,
24, 26, 35, 41, 64, 65]. The technique has been applied in studies of novel systems
where the pharmacodynamic response behaves non-linearly, where time-lags are
present, and when functional adaptation is manifested [24]. These examples315
demonstrate the potential of DRT modelling in characterizing mechanisms of
action of complex pharmacological systems. The present study extends the util-
ity of a non-linear biophase model, permitting the description of more complex
absorption kinetics. The non-invasiveness of DRT analysis promotes its use
when excessive sampling is prohibited (small animals, paedriatic populations)320
[60].
4.1. DRT modelling
DRT data analysis typically requires response-time series with higher resolu-
tion than traditional traditional exposure-driven studies. This is because kinetic
information in response-time data are sought for the biophase turnover.325
In contrast to exposure-driven pharmacodynamic modelling, the biophase
kinetics and the pharmacodynamic properties of a DRT model must be esti-
mated simultaneously. This may in some instances lead to diﬃculties in sepa-
rating confounding factors originating from either the concentration-time or the
response-time course or both. If, for example, drug absorption and disposition330
is highly non-linear this may confound the interpretation of nonlinear pharma-
coynamics. Therefore, a priori knowledge about the mechanism(s) of action is
necessary for construction of an adequate biophase model.
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4.2. Strategy when selecting the biophase model
The structure of the biophase model is preferably derived through a series335
of steps where data from diﬀerent administration routes are sequentially imple-
mented and the biophase is structure reﬁned if necessary. In this way, diﬀerent
properties, for example elimination rate and absorption rate, can be addressed
separately.
In this study, the intravenous data were initially analysed in order to ad-340
dress the biophase disposition. Both a linear ﬁrst-order and a Michaelis-Menten
elimination model were successfully ﬁtted to the data. The two models had ap-
proximately the same objective function values and ﬁtted the data equally well
when the function plots were inspected graphically. However, when the AIC
was applied, the simpler model was preferred, and therefore selected. The sim-345
ilarity between the linear ﬁrst-order and Michaelis-Menten elimination models
was due to the high estimate of the Michaelis-Menten constant, in comparison
to the biophase amounts, rendering an approximately linear elimination rate at
all dose levels.
When the disposition model was set, oral data were included and the absorp-350
tion process into the biophase was assessed. Both a ﬁrst-order and nonlinear
Michaelis-Menten absorption model were ﬁtted to the data. The ﬁrst-order
absorption model failed to capture the full dynamic behaviour of the data in
that it systematically over-predicted the response-time course for the highest
oral dose (812 µmol kg−1). This problem was resolved by the Michaelis-Menten355
absorption model that also captured the absorption-rate limited elimination.
4.3. The NiAc/FFA DRT model
The model captures the general trends of the populations and the Monte
Carlo prediction intervals span most of the individuals.
The population ﬁts in Fig. 4 indicate that the population medians diﬀer360
slightly from the individual behaviours for the infusion of 0.033 µmol kg−1min−1
(Fig. 4a), which is predicted to be higher than the individual outcomes, and
the oral dose of 81.2 µmol kg−1 (Fig. 4i), which is predicted to be lower than
the individual outcomes. This diﬀerence is believed to be an artefact of inter-
occasional variability since these populations have lower (for the infusion of365
0.033 µmol kg−1min−1), respectively higher (for the oral dose of 81.2 µmol kg−1),
baseline values than the estimated population baseline. A potential way to avoid
this issue is to model the inter-occasional variations.
The eight moderator compartments were chosen to model the slow and fast
action of insulin and other hormones. A more eloquent way would be to optimize370
the number of compartments as a system parameter or use another time-delay
relation, such as the actual insulin concentration-time course. This is a matter
for future model reﬁnement.
The integral feedback control, moderator feedback, and the turnover of FFA
are shown to act over diﬀerent time-scales (Table 3). Turnover of FFA occurs375
within minutes, the feedback triggered by insulin and other hormones operates
within 30 minutes, while the slow buildup of NiAc tolerance occurs within a
12
couple of hours.
The model predicts full system adaptation for long-term constant rate infu-
sions with the therapeutic infusion rate of 0.17 µmol kg−1min−1 (Fig. 7). This380
illustrates the eﬀect of the integral feedback control, which forces the response
back to baseline over time. Homeostatic behaviour has been proven experimen-
tally in studies of long-term NiAc provocation [45]. However, 90% of adaptation
typically occurs within 24 h at therapeutic concentrations of NiAc. A better es-
timate for the adaptation Ki is expected when longitudinal data are generated385
and added to the analysis.
In general, there is high consistency between our derived system parameter
estimates and the ones from exposure-driven analysis. The slight deviations are
still within reasonable biological limits given the parameter uncertainty (Table
4). This comparison strengthens the use of DRT analysis as a complementary390
technique in studies where limited exposure data are available.
The proposed biophase model is per se a substantial simpliﬁcation in com-
parison to the original multi-compartment plasma kinetics (exposure) model
that has been applied by others (Iwaki et al. [34], Ahlström et al. [7] and
Tapani et al. [59]). Therefore, dose predictions, impact of diﬀerent dosing regi-395
mens, or assessment of safety margins will probably require an exposure-driven
approach.
This study has demonstrated the utility of DRT modelling by developing
biophase-driven pharmacodynamic models. The biophase structure was chal-
lenged by means of diﬀerent rates, routes, and modes of administration, on top400
of the pharamcodynamic complexities.
We envision that DRT data analysis will have great signiﬁcance on phar-
macological responses (biomarkers) used in the future assessment of dynamics.
DRT analysis has proven to be an acceptable alternative to exposure-driven PD
modelling in situations where plasma concentrations are sparse or missing, or405
if extreme diﬀerences are seen for the initial and terminal disposition phases in
plasma (such as with oligonucleotides, where rate and extent of exposure vary
signiﬁcantly between tissues [15, 31]).
4.4. Control theory
In this study, techniques from systems and control theory were utilized to410
describe feedback mechanisms and systemic adaptation. By applying integral
feedback control the system demonstrated full adaptation under constant long-
term NiAc pressure (see Fig. 7). In fact, integral feedback control is a prereq-
uisite for perfect adaptation in systems that experience constant disturbance
[10, 56].415
The control theory feature of the pharmacodynamic model provides a sig-
niﬁcant improvement in comparison to previously published NiAc/FFA models
[7, 59], and will make the model better suited for chronic regimens.
Many biological systems, experiencing adaptation when put under external
disturbance, have been successfully modelled by means of control theory tech-420
niques, including metabolic networks [30], synthetic biology [17], the osmoreg-
ulation in yeast [27, 42], and bacterial chemotaxis [12, 66]. El-Samad et al.
13
showed how integral feedback control could, for example, be derived from enzy-
matic relations when the goal is to address the control of plasma calcium levels
[19]. Control theory techniques have been used sparsely within PK-PD mod-425
elling and mostly in dose control [52, 57, 61, 63, 62]. Control theory techniques
have a clear potential in modelling intrinsic control and feedback systems.
4.5. Inter-individual and intra-individual variability
When the model was ﬁtted for each individual separately (i.e., without a
mixed-eﬀects approach) the parameter estimates of R0, k, kout, ktol, and Ki430
had large coeﬃcients of variation, indicating that the data contained enough
information to estimate the corresponding η's of these parameters (i.e. the
individual parameters) in a mixed-eﬀects approach. However, no parametric
model (e.g., normal or log-normal) was successfully matched to the distributions
of the EBE's. Regardless, a log-normal distribution was chosen to model the435
EBE's spread due the positive range of the log-normal distribution, a generic
feature expected in the parameters. Use of a log-normal model led to high
levels of shrinkage in some of the EBE's. Whilst R0 and k had low η-shrinkages,
indicating that the log-normal assumption on the parameter distributions was
reasonable, the remaining three parameters (kout, ktol, and Ki) had high η-440
shrinkages of 40 − 60%, indicating that the log-normal distribution does not
describe these parameters in a satisfactory way. Thus, one should be careful
not to over-interpret the values of the EBE's. This includes EBE vs EBE plots
or EBE vs covariate plots, which are not reliable under high levels of shrinkage.
For that reason, analyses of these kinds are omitted in this study. However,445
the estimated random eﬀects are still useful when describing the data and when
extrapolating to, for example, other dosing regimens.
Both of the models used for the infusion and oral data gave reasonably low
ε-shrinkages of less than 10% indicating that the models describe the data in a
satisfactory manner without being over-ﬁtted.450
4.6. New numerical algorithms
The new numerical algorithms used rely on sensitivity equations to calculate
the gradients in the optimization routine. This improves precision and accu-
racy extensively in comparison to ﬁnite diﬀerence approximations, increasing
the chance of convergence in the parameter estimation for computer-intensive455
models [9].
5. Conclusions
A DRTmodel was successfully ﬁtted to all time courses available of the NiAc-
induced changes in FFA in normal rats, showing the versatility of this approach.
A nonlinear biophase model was used to describe saturable absorption. Using460
moderator compartments, and systems and control theory, we captured diﬀerent
feedback mechanisms. The systems and control theory techniques was success-
fully applied to describe complete system adaptation under constant long-term
14
exposure to NiAc. This provides a signiﬁcant improvement of the previously
used NiAc/FFA models and will be suited in chronic regimens. Consistency in465
pharmacodynamic parameters between biophase- and kinetic-driven studies in-
dicates potentially wider use of DRT data analysis. New numerical approaches
were successfully applied to robustly and eﬃciently compute the gradients in
the nonlinear mixed-eﬀects framework.
DRT analysis is generally a poorly explored area that has great potential470
and could be considered more frequently in future pharmacological studies when
drug exposure data are scarce or even lacking.
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Appendix A
The following is an excerpt from the modelling code used, implemented in480
Mathematica. An executable version of this code, with corresponding data sets
used for this study, is available from the authors upon request.
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Figure 3: Schematic structure of the pharmacodynamics of the DRT feedback model. The
pharmacodynamic model structure consists of a turnover equation coupled with a chain of
moderator compartments, with slow and rapid feedback, as well as a slow integral control
feedback. Here kin denotes the turnover rate of FFA, kout the fractional turnover rate of
FFA, ktol the turnover rate of the moderators, p the ampliﬁcation factor, I(Ab) the drug-
mechanism function, and M1 and M8 the ﬁrst and last moderator, respectively. Solid lines
represent ﬂuxes whilst the dashed lines represent ﬂow of information (i.e., how the diﬀerent
entities aﬀect one another)
25
(a
)
(b
)
(c
)
(d
)
(e
)
(f
)
(g
)
(h
)
(i
)
(j
)
(k
)
F
ig
u
r
e
4
:
P
o
p
u
la
ti
o
n
m
o
d
el
ﬁ
ts
to
th
e
F
F
A
re
sp
o
n
se
le
v
el
s,
w
it
h
9
0
%
M
o
n
te
C
a
rl
o
p
re
d
ic
ti
o
n
in
te
rv
a
ls
.
T
h
e
b
la
ck
li
n
es
re
p
re
se
n
t
th
e
es
ti
m
a
te
d
p
o
p
u
la
ti
o
n
m
ed
ia
n
,
th
e
lo
w
er
b
la
ck
d
a
sh
ed
li
n
es
a
n
d
th
e
u
p
p
er
b
la
ck
d
a
sh
ed
li
n
es
re
p
re
se
n
t
th
e
5
%
-q
u
a
n
ti
le
a
n
d
th
e
9
5
%
-q
u
a
n
ti
le
o
f
th
e
M
o
n
te
C
a
rl
o
p
re
d
ic
ti
o
n
in
te
rv
a
l,
re
sp
ec
ti
v
el
y.
T
h
e
co
lo
u
re
d
li
n
es
a
re
th
e
m
ea
su
re
d
in
d
iv
id
u
a
l
F
F
A
re
sp
o
n
se
le
v
el
s.
(a
-c
)
re
p
re
se
n
t
3
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.0
3
3
,
0
.1
7
,
a
n
d
0
.6
7
µ
m
o
lk
g
−
1
m
in
−
1
,
re
sp
ec
ti
v
el
y
;
(d
-f
)
re
p
re
se
n
t
3
0
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.0
1
7
,
0
.0
3
3
,
a
n
d
0
.1
7
µ
m
o
lk
g
−
1
m
in
−
1
,
re
sp
ec
ti
v
el
y
;
(g
)
re
p
re
se
n
ts
a
3
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.1
7
µ
m
o
lk
g
−
1
m
in
−
1
fo
ll
ow
ed
b
y
a
st
ep
w
is
e
d
ec
re
a
se
in
in
fu
si
o
n
ra
te
to
ze
ro
ev
er
y
1
0
m
in
fo
r
1
8
0
m
in
;
a
n
d
(h
)
re
p
re
se
n
ts
a
3
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.1
7
µ
m
o
lk
g
−
1
m
in
−
1
fo
ll
ow
ed
b
y
a
st
ep
w
is
e
d
ec
re
a
se
in
in
fu
si
o
n
ra
te
to
ze
ro
ev
er
y
1
0
m
in
fo
r
1
8
0
m
in
fo
ll
ow
ed
b
y
a
n
o
th
er
3
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.1
7
µ
m
o
lk
g
−
1
m
in
−
1
.
(i
-k
)
re
p
re
se
n
t
o
ra
l
d
o
si
n
g
o
f
2
4
.4
,
8
1
.2
,
a
n
d
8
1
2
µ
m
o
lk
g
−
1
,
re
sp
ec
ti
v
el
y
26
(a
)
(b
)
(c
)
(d
)
(e
)
(f
)
(g
)
(h
)
(i
)
(j
)
(k
)
F
ig
u
r
e
5
:
P
o
p
u
la
ti
o
n
m
o
d
el
p
re
d
ic
ti
o
n
s
o
f
th
e
b
io
p
h
a
se
d
ru
g
a
m
o
u
n
t
o
n
a
se
m
i-
lo
g
a
ri
th
m
ic
sc
a
le
.
T
h
e
b
la
ck
li
n
es
re
p
re
se
n
t
th
e
es
ti
m
a
te
d
b
io
p
h
a
se
d
ru
g
a
m
o
u
n
t
a
n
d
th
e
b
lu
e
d
a
sh
ed
li
n
es
re
p
re
se
n
t
th
e
p
re
d
ic
te
d
ID
5
0
es
ti
m
a
te
.
(a
-c
)
re
p
re
se
n
t
3
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.0
3
3
,
0
.1
7
,
a
n
d
0
.6
7
µ
m
o
lk
g
−
1
m
in
−
1
,
re
sp
ec
ti
v
el
y
;
(d
-f
)
re
p
re
se
n
t
3
0
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.0
1
7
,
0
.0
3
3
,
a
n
d
0
.1
7
µ
m
o
lk
g
−
1
m
in
−
1
,
re
sp
ec
ti
v
el
y
;
(g
)
re
p
re
se
n
ts
a
3
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.1
7
µ
m
o
lk
g
−
1
m
in
−
1
fo
ll
ow
ed
b
y
a
st
ep
w
is
e
d
ec
re
a
se
in
in
fu
si
o
n
ra
te
to
ze
ro
ev
er
y
1
0
m
in
fo
r
1
8
0
m
in
;
(h
)
re
p
re
se
n
ts
a
3
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.1
7
µ
m
o
lk
g
−
1
m
in
−
1
fo
ll
ow
ed
b
y
a
st
ep
w
is
e
d
ec
re
a
se
in
in
fu
si
o
n
ra
te
to
ze
ro
ev
er
y
1
0
m
in
fo
r
1
8
0
m
in
a
n
d
fo
ll
ow
ed
b
y
a
n
o
th
er
3
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.1
7
µ
m
o
lk
g
−
1
m
in
−
1
.
(i
-k
)
re
p
re
se
n
t
o
ra
l
d
o
si
n
g
o
f
2
4
.4
,
8
1
.2
,
a
n
d
8
1
2
µ
m
o
lk
g
−
1
,
re
sp
ec
ti
v
el
y
27
(a
)
(b
)
(c
)
(d
)
(e
)
(f
)
(g
)
(h
)
(i
)
(j
)
(k
)
F
ig
u
r
e
6
:
In
d
iv
id
u
a
ll
y
ﬁ
tt
ed
F
F
A
re
sp
o
n
se
-t
im
e
co
u
rs
es
.
(a
-c
)
re
p
re
se
n
t
3
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.0
3
3
,
0
.1
7
,
a
n
d
0
.6
7
µ
m
o
lk
g
−
1
m
in
−
1
,
re
sp
ec
ti
v
el
y
;
(d
-f
)
re
p
re
se
n
t
3
0
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.0
1
7
,
0
.0
3
3
,
a
n
d
0
.1
7
µ
m
o
lk
g
−
1
m
in
−
1
,
re
sp
ec
ti
v
el
y
;
(g
)
re
p
re
se
n
ts
a
3
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.1
7
µ
m
o
lk
g
−
1
m
in
−
1
fo
ll
ow
ed
b
y
a
st
ep
w
is
e
d
ec
re
a
se
in
in
fu
si
o
n
ra
te
to
ze
ro
ev
er
y
1
0
m
in
fo
r
1
8
0
m
in
;
(h
)
re
p
re
se
n
ts
a
3
0
-m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.1
7
µ
m
o
lk
g
−
1
m
in
−
1
fo
ll
ow
ed
b
y
a
st
ep
w
is
e
d
ec
re
a
se
in
in
fu
si
o
n
ra
te
to
ze
ro
ev
er
y
1
0
m
in
fo
r
1
8
0
m
in
a
n
d
fo
ll
ow
ed
b
y
a
n
o
th
er
3
0
m
in
co
n
st
a
n
t
ra
te
in
fu
si
o
n
o
f
0
.1
7
µ
m
o
lk
g
−
1
m
in
−
1
a
n
d
(i
-k
)
re
p
re
se
n
t
o
ra
l
d
o
si
n
g
o
f
2
4
.4
,
8
1
.2
,
a
n
d
8
1
2
µ
m
o
lk
g
−
1
,
re
sp
ec
ti
v
el
y
28
T
a
b
le
2
:
D
R
T
m
o
d
el
p
a
ra
m
et
er
es
ti
m
a
te
s
a
n
d
in
te
r-
in
d
iv
id
u
a
l
va
ri
a
ti
o
n
s,
ex
p
re
ss
ed
in
C
V
%
,
w
it
h
co
rr
es
p
o
n
d
in
g
re
la
ti
v
e
st
a
n
d
a
rd
er
ro
rs
(R
S
E
%
),
a
n
d
η
-s
h
ri
n
ka
g
es
P
a
ra
m
et
er
D
eﬁ
n
it
io
n
E
st
im
a
te
II
V
η
-s
h
ri
n
ka
g
e
V
m
a
x
,g
(µ
m
ol
k
g
−
1
m
in
−
1
)
M
a
x
.
el
im
in
a
ti
o
n
ra
te
fr
o
m
g
u
t
5
.3
7
(0
.9
7
)
-
-
K
m
,g
(µ
m
ol
k
g
−
1
)
A
m
o
u
n
t
in
g
u
t
a
t
h
a
lf
V
m
a
x
,g
3
7
.1
(3
.4
)
-
-
k
(m
in
−
1
)
B
io
p
h
a
se
el
im
in
a
ti
o
n
ra
te
0
.4
4
6
(5
.8
)
4
5
.1
(2
3
)
2
1%
R
0
(m
m
ol
l−
1
)
B
a
se
li
n
e
F
F
A
co
n
c.
0
.7
0
5
(2
.3
)
2
1
.1
(3
7
)
4
.2
%
k
o
u
t
(m
in
−
1
)
F
ra
ct
io
n
a
l
tu
rn
ov
er
ra
te
0
.3
0
6
(8
.1
)
4
2
.4
(4
7
)
4
6
%
k
to
l
(m
in
−
1
)
T
u
rn
ov
er
ra
te
o
f
m
o
d
er
a
to
r
0
.0
2
4
2
(5
.2
)
2
4
.4
(9
8
)
5
2
%
K
i
(m
in
−
1
)
A
d
a
p
ta
ti
o
n
ra
te
0
.0
0
1
7
4
(2
5
)
9
0
.6
(2
3
)
5
8
%
p
A
m
p
li
ﬁ
ca
ti
o
n
fa
ct
o
r
0
.8
1
9
(4
.7
)
-
-
I m
a
x
E
ﬃ
ca
cy
0
.8
8
1
(2
.8
)
-
-
ID
5
0
(µ
m
ol
k
g
−
1
)
P
o
te
n
cy
0
.0
4
5
6
(6
.8
)
-
-
γ
H
il
l
ex
p
o
n
en
t
2
.9
6
(8
.6
)
-
-
29
Table 3: Estimated system rate constants and their corresponding half-lives (in minutes)
with 90% non-parametric bootstrap prediction intervals
Parameter Estimate Half-life 90% PIa
kout (min
−1) 0.31 2.3 [1.3, 4.0]
ktol (min
−1) 0.024 29 [15, 51]
Ki (min
−1) 0.0017 400 [210, 710]
a90% non-parametric bootstrap prediction interval
Table 4: Comparison between the dynamic parameter estimates from the DRT study and
an exposure-driven study. The parameter estimates are given with corresponding relative
standard errors (RSE%)
Parameter DRT analysis Exposure-response anal.
kout (min
−1) 0.306(8.1) 0.244(7.3)
ktol (min
−1) 0.0242(5.2) 0.0222(2.7)
Ki (min
−1) 0.00174(25) 0.00160(18)
p 0.819(4.7) 0.859(3.7)
Imax 0.881(2.8) 0.907(0.63)
γ 2.96(8.6) 2.36(9.2)
Figure 7: The long-term model-predicted eﬀect of NiAc provocation on FFA level in normal
rats with an infusion rate of 0.17µmol kg−1min−1 (aiming at a therapeutic NiAc concentration
of 1µmol [4]) during 10 days. The inserted ﬁgure shows in more detail the dynamics during
the ﬁrst day of NiAc infusion
Table 5: Model residual additive errors with corresponding relative standard errors (RSE%)
and ε-shrinkage for infusion and oral data, respectively
Data Residual add. error σ ε-shrinkage
Infusion 0.0982(14) 9.5%
Oral 0.149(5.0) 7.7%
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[t]
,
kt
ol
M7[
t]-
M8
[t]
,1
-R[t
]R
0;
ic
={A
b[0]
,R
[0],
M1
[0],
M2
[0],
M3
[0],
M4
[0],
M5
[0],
M6
[0],
M7
[0],
M8
[0],
y[0]
}⩵
{0,
R0
,R
0,
R0
,R
0,
R0
,R
0,
R0
,R
0,
R0
,0
};
ou
t
= {R[ t]
};
or
al
Sy
s={
Aa
'[t]
,A
b'
[t],
R'
[t],
M1
'[t]
,M
2'
[t],
M3
'[t]
,M
4'
[t],
M5
'[t]
,M
6'
[t],
M7
'[t]
,M
8'
[t],
y'
[t]}
⩵
-aV
ma
x*A
a[t]
/(aK
m+A
a[t]
),b
io
In
pu
t-k
b*A
b[t]
,
1+
Ki
*y[t
]*
ki
n*
1-
Im
ax
*Ab[
t]^γ
ID
50
^γ+
Ab
[t]^
γ*
R0
M1
[t]
^p
-
ko
ut
*R[t
]*
M8
[t]
R0
,
kt
ol
R[t
]-M
1[t]
,kt
ol
M1[
t]-
M2
[t]
,k
to
lM2
[t]-
M3
[t]
,
kt
ol
M3[
t]-
M4
[t]
,k
to
l(M4
[t]-
M5
[t])
,k
to
lM5
[t]-
M6
[t]
,
kt
ol
M6[
t]-
M7
[t]
,k
to
lM7
[t]-
M8
[t]
,
1-R
[t]
R0
;
or
al
Ic
={A
a[0]
,A
b[0]
,R
[0],
M1
[0],
M2
[0],
M3
[0],
M4
[0],
M5
[0],
M6
[0],
M7
[0],
M8
[0],
y[0]
}⩵{
ab
sI
np
ut
,0
,R
0,
R0
,R
0,
R0
,R
0,
R0
,R
0,
R0
,R
0,
0};
S
pe
ci
fy
 in
pu
t
bi
oI
np
ut
Fu
nc
ti
on
s
=R
AT
E*U
ni
tS
te
p[DO
SE
/RAT
E-t
],R
AT
E*U
ni
tS
te
p[30
-t]
+
Pi
ec
ew
is
e
RA
TE
-Cei
li
ng
t-
30
1
0*
RA
TE
19,
t>3
0&
&t
<21
0
+
Pi
ec
ew
is
e
RA
TE
*Uni
tS
te
p21
0+
DO
SE
-20
RAT
E-t
,t
>21
0
,
Aa
[t]*
aV
ma
x/(
aK
m+A
a[t]
);
ab
sI
np
ut
Fu
nc
ti
on
s
={R
AT
E*D
OS
E};
S
pe
ci
fy
 s
ys
te
m
s
in
fS
ys
=sy
s/.
Th
re
ad
[bio
In
pu
t→b
io
In
pu
tF
un
ct
io
ns
[[1]
]]/
.f
ix
ed
Pa
ra
mR
ul
es
;
st
ep
Sy
s
=sy
s/.
Th
re
ad
[bio
In
pu
t
→bi
oI
np
ut
Fu
nc
ti
on
s[[2
]]]
/.f
ix
ed
Pa
ra
mR
ul
es
;
or
al
Sy
s
=or
al
Sy
s/.
Th
re
ad
[bio
In
pu
t→b
io
In
pu
tF
un
ct
io
ns
[[3]
]]/
.f
ix
ed
Pa
ra
mR
ul
es
;
D
ef
in
e 
ra
nd
om
 v
ar
ia
bl
es
 (i
.e
. m
ul
tip
lic
at
iv
e 
ra
nd
om
 n
oi
se
s 
to
 c
er
ta
in
 p
ar
am
et
er
s,
 h
er
e 
ID
50
, k
ou
t, 
R
0 
an
d 
K
i)
ra
nd
om
Pa
ra
ms
={η
1,
η2,η
3,
η4,η
5};
S
et
tin
g 
up
 m
od
el
s 
co
ns
is
tin
g 
of
 {s
ys
}, 
{ic
}, 
ou
t
mo
de
l1
={{
in
fS
ys
},{
ic
},o
ut
}/.
ra
nd
om
Ef
fe
ct
s;
mo
de
l2
={{
st
ep
Sy
s},
{ic}
,o
ut
}/.
ra
nd
om
Ef
fe
ct
s;
mo
de
l3
={{
or
al
Sy
s},
{ora
lI
c}/
.T
hr
ea
d[ab
sI
np
ut
→ab
sI
np
ut
Fu
nc
ti
on
s],
ou
t}/
.r
an
do
mE
ff
ec
ts
;
mo
de
ls
={m
od
el
1,
mo
de
l2
,m
od
el
3};
D
ef
in
e 
O
m
eg
a 
(in
te
rin
di
vi
du
al
 v
ar
ia
tio
n)
L={
{ω11
,
0,
0,
0,
0},
{0,
ω22,
0,
0,
0},
{0,
0,
ω33,
0,
0},
{0,
0,
0,
ω44,
0},
{0,
0,
0,
0,
ω55}
};
Ω=L
.T
ra
ns
po
se
[L];
D
ef
in
e 
th
e 
S
 m
at
rix
 fo
r a
ll 
m
od
el
s 
(m
ea
su
rm
en
t n
oi
se
)
S1
={{
s1
}};
S2
={{
s2
}};
S3
={{
s3
}};
SL
is
t
={S
1,
S2
,S
3};
C
on
st
ru
ct
 a
 d
at
a 
lis
t o
f d
at
a 
fro
m
 a
ll 
m
od
el
s.
 In
 th
is
 c
as
e,
 w
ith
 o
nl
y 
on
e 
ad
m
in
is
tra
tio
n 
ro
ut
e,
 th
e 
lis
t 
on
ly
 c
on
sa
in
s 
a 
si
ng
le
 m
od
el
. 
in
fD
at
a
={J
oi
n[pr
ep
Da
ta
Do
se
0T
im
e0
,p
re
pD
at
aD
os
e1
Ti
me
30
,
pr
ep
Da
ta
Do
se
5T
im
e3
0,
pr
ep
Da
ta
Do
se
20
Ti
me
30
,p
re
pD
at
aD
os
e5
Ti
me
30
0,
pr
ep
Da
ta
Do
se
10
Ti
me
30
0,
pr
ep
Da
ta
Do
se
51
Ti
me
30
0]};
st
ep
Da
ta
={J
oi
n[pr
ep
Da
ta
Do
se
20
,p
re
pD
at
aD
os
e2
5]};
or
al
Da
ta
=
{Joi
n[pr
ep
Da
ta
Or
al
Do
se
24
,p
re
pD
at
aO
ra
lD
os
e8
1,
pr
ep
Da
ta
Or
al
Do
se
81
2]};
da
ta
=Jo
in
[inf
Da
ta
,s
te
pD
at
a,
or
al
Da
ta
];
D
ef
in
e 
al
l n
on
 y
et
 d
ef
in
ed
 c
on
st
an
ts
 o
f t
he
 s
ys
te
m
li
st
Of
In
pu
ts
={D
OS
E,
RA
TE
};
C
on
st
ru
ct
 a
 p
ar
am
et
er
 li
st
 w
ith
 a
ll 
th
e 
pa
ra
m
et
er
s
pa
ra
me
te
rS
ta
rt
Va
lu
e
={{
aV
ma
x,
5},
{aKm
,3
0},
{θ1,
2},
{kb,
0.
3},
{Ki,
0.
00
1},
{ID5
0,
0.
05
},{
ko
ut
,0
.3
0},
{R0,
0.
70
},{
γ,1}
,{k
to
l,
0.
03
},{
p,
1}};
ωSta
rt
Va
lu
e
={{
ω11,
0.
1},
{ω22
,0
.1
},{
ω33,
0.
1},
{ω44
,0
.1
},{
ω55,
0.
1}};
sS
ta
rt
Va
lu
e
={{
s1
,0
.1
},{
s2
,0
.1
},{
s3
,0
.1
}};
fu
ll
Pa
ra
me
te
rL
is
t
=Jo
in
[par
am
s,
{s1,
s2
,s
3}];
E
st
im
at
io
n 
of
 p
ar
am
et
er
s
{pEx
pV
al
ue
s,
pV
al
ue
s,
hi
st
or
y}=
Fi
tP
op
ul
at
io
nM
od
el
[dat
a,
mo
de
ls
,l
is
tO
fI
np
ut
s,
pa
ra
me
te
rS
ta
rt
Va
lu
e,
{SLi
st
,s
St
ar
tV
al
ue
},{
ra
nd
om
Pa
ra
ms
,Ω,
ωSta
rt
Va
lu
e},
t,
fu
ll
Pa
ra
me
te
rL
is
t];
2
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